Hartmann, A.

patient tacrolimu study person transplantation mutation bladder crime analysis group fgfr 3 mutations article cyp 3a tumours cancer urothelial corruption cyp 3a genotype concentration transplant grade dutch marker exposure measure information tumor rejection polymorphism authority bribery month table cyp 3a expressers genotype pharmacokinetic pattern carcinoma transplant recipients mpa auc 0–12 sector expression entity mycophenolic acid offences value university ck 20 pattern recipient system progression status cyp 3a nonexpressers fgfr 3 mutation mycophenolic difference bladder cancer day 3 ck 20 expression european fgfr 3 status mpa exposure fgfr 3 drug monitoring organisation pathol recurrence kidney cyp 3a allele survival offence mycophenolate result therapy cyclosporine mofetil stage growth activity -67